Featured Research

from universities, journals, and other organizations

Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks

Date:
September 26, 2011
Source:
Canadian Medical Association Journal
Summary:
Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of bleeding than patients taking ASA alone, according to a study in CMAJ.

Heart attack patients taking selective serotonin reuptake inhibitors (SSRIs) in combination with antiplatelet therapy -- acetylsalicylic acid (ASA), clopidogrel or both (dual antiplatelet therapy) -- are at higher risk of bleeding than patients taking ASA alone, according to a study in CMAJ (Canadian Medical Association Journal).

Related Articles


Antiplatelet therapy is commonly prescribed for patients who have had heart attacks to reduce the likelihood of another attack. There is, however, a risk of bleeding, which increases when certain other medications such as anticoagulants or SSRIs are taken at the same time as antiplatelet therapy.

SSRIs are commonly prescribed for depression. Many patients have symptoms of depression after a heart attack.

The study in CMAJ looked at 27 058 patients aged 50 years or older between 1997 and 2007. More than half were taking ASA alone and about 3% were taking SSRIs along with antiplatelet therapy. Researchers found that although ASA and clopidogrel taken on their own have a similar risk of bleeding, combining an SSRI with ASA increased the risk by 42%, and combining SSRI use with dual antiplatelet therapy increased the risk by 57%. Women appeared to have a decreased risk of bleeding, as did patients who had angioplasty as an intervention after their heart attack.

Bleeding includes gastrointestinal bleeding, hemorrhagic stroke or other bleeding that required hospitalization or occurred in hospital during treatment.

"Ultimately, clinicians must weigh the benefits of SSRI therapy against the risk of bleeding in patients with major depression following acute myocardial infarction," write the authors. They conclude physicians must be cautious when prescribing antidepressants.


Story Source:

The above story is based on materials provided by Canadian Medical Association Journal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christopher Labos, Kaberi Dasgupta, Hacene Nedjar, Gustavo Turecki, Elham Rahme. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. Canadian Medical Association Journal, September 26, 2011 DOI: 10.1503/cmaj.100912

Cite This Page:

Canadian Medical Association Journal. "Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks." ScienceDaily. ScienceDaily, 26 September 2011. <www.sciencedaily.com/releases/2011/09/110926131802.htm>.
Canadian Medical Association Journal. (2011, September 26). Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/09/110926131802.htm
Canadian Medical Association Journal. "Increased risk of bleeding with combined use of SSRIs and antiplatelet therapy after heart attacks." ScienceDaily. www.sciencedaily.com/releases/2011/09/110926131802.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins